While there have been notable successes (for example, anti-CD20 for hematologic malignancies, anti-human epidermal growth factor receptor 2 (HER2) for breast cancer, and anti-GD2 for neuroblastoma), most mAbs have failed to improve outcomes despite their initial promise, especially in pediatric sarcomas. This evidence concerns the gene ERBB2 and cancer.